Next-Gen IL-1α Antibodies

About XBiotech

XBiotech's mission is to develop safer, more effective antibody therapies by harnessing natural human immunity, guided by a 'do no harm' principle. Its key achievement was the 2019 sale of its lead IL-1α antibody, bermekimab, for $750M upfront, providing substantial non-dilutive capital. The company's strategy leverages its fully integrated True Human™ platform—encompassing proprietary discovery (SHSAM™), genetic cloning, and in-house manufacturing—to build a pipeline targeting high-need areas in inflammation, oncology, and anti-infectives. XBiotech is now advancing multiple clinical and pre-clinical candidates from its 48-acre Austin campus.

Therapeutic Areas